Synonym
GS-143; GS 143; GS143;
IUPAC/Chemical Name
4-[4-[[5-(2-Fluorophenyl)-2-furanyl]methylene]-4,5-dihydro-5-oxo-3-(phenylmethyl)-1H-pyrazol-1-yl]benzoic acid
InChi Key
IZPMWFSVTDOCDI-HAVVHWLPSA-N
InChi Code
InChI=1S/C28H19FN2O4/c29-24-9-5-4-8-22(24)26-15-14-21(35-26)17-23-25(16-18-6-2-1-3-7-18)30-31(27(23)32)20-12-10-19(11-13-20)28(33)34/h1-15,17H,16H2,(H,33,34)/b23-17+
SMILES Code
O=C(O)C1=CC=C(N2N=C(CC3=CC=CC=C3)/C(C2=O)=C\C4=CC=C(C5=CC=CC=C5F)O4)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
GS143 is a selec¬tive IκBα ubiquitination inhibitor with an IC50 of 5.2 μM for SCFβTrCP1-mediated IκBα ubiquitylation. GS143 sup-presses NF-κB acti¬va¬tion and tran¬scrip¬tion of tar¬get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect.
In vitro activity:
Here, this study describes a novel inhibitor termed GS143, which suppressed IkappaBalpha ubiquitylation, but not IkappaBalpha phosphorylation, MDM2-directed p53 ubiquitylation, and proteasome activity in vitro.
Reference: Biophys Res Commun. 2008 Apr 18;368(4):1007-13. https://pubmed.ncbi.nlm.nih.gov/18275844/
In vivo activity:
Intranasal administration of GS143 prior to antigen challenge suppressed antigen-induced NF-kappaB activation in the lung of sensitized mice. Intranasal administration of GS143 also inhibited antigen-induced eosinophil and lymphocyte recruitment into the airways as well as the expression of Th2 cytokines and eotaxin in the airways.
Reference: Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. https://pubmed.ncbi.nlm.nih.gov/18656449/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
25.0 |
53.59 |
| DMF:PBS (pH 7.2) (1:4) |
0.2 |
0.43 |
| DMSO |
31.4 |
67.28 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
466.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Hirose K, Wakashin H, Oki M, Kagami S, Suto A, Ikeda K, Watanabe N, Iwamoto I, Furuichi Y, Nakajima H. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. doi: 10.1016/j.bbrc.2008.07.072. Epub 2008 Jul 24. PMID: 18656449.
2. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13. doi: 10.1016/j.bbrc.2008.01.166. Epub 2008 Feb 12. PMID: 18275844.
In vitro protocol:
1. Hirose K, Wakashin H, Oki M, Kagami S, Suto A, Ikeda K, Watanabe N, Iwamoto I, Furuichi Y, Nakajima H. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. doi: 10.1016/j.bbrc.2008.07.072. Epub 2008 Jul 24. PMID: 18656449.
2. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13. doi: 10.1016/j.bbrc.2008.01.166. Epub 2008 Feb 12. PMID: 18275844.
In vivo protocol:
1. Hirose K, Wakashin H, Oki M, Kagami S, Suto A, Ikeda K, Watanabe N, Iwamoto I, Furuichi Y, Nakajima H. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. doi: 10.1016/j.bbrc.2008.07.072. Epub 2008 Jul 24. PMID: 18656449.
2. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13. doi: 10.1016/j.bbrc.2008.01.166. Epub 2008 Feb 12. PMID: 18275844.
1: Rashmi BS, Gayathri D. Molecular characterization of gluten hydrolysing Bacillus sp. and their efficacy and biotherapeutic potential as probiotics using Caco-2 cell line. J Appl Microbiol. 2017 Sep;123(3):759-772. doi: 10.1111/jam.13517. Epub 2017 Aug 4. PubMed PMID: 28637081.
2: Chen S, Wei YJ, Chen MM, Zhang ZT. Bilateral treatment: a strategy for enhancing the mechanical strength of machinable veneers. Dent Mater. 2010 Oct;26(10):961-7. doi: 10.1016/j.dental.2010.05.011. Epub 2010 Jul 23. PubMed PMID: 20655583.
3: Hirose K, Wakashin H, Oki M, Kagami S, Suto A, Ikeda K, Watanabe N, Iwamoto I, Furuichi Y, Nakajima H. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun. 2008 Sep 26;374(3):507-11. doi: 10.1016/j.bbrc.2008.07.072. Epub 2008 Jul 24. PubMed PMID: 18656449.
4: Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun. 2008 Apr 18;368(4):1007-13. doi: 10.1016/j.bbrc.2008.01.166. Epub 2008 Feb 12. PubMed PMID: 18275844.
